Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ305MR)

This product GTTS-WQ305MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Colon sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ305MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4917MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ1077MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ12294MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ11905MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ4067MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ1567MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ9165MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ14770MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-35
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW